|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,316,067: Scope, Claims, and Patent Landscape
Summary
United States Patent 7,316,067, granted to AbbVie, covers a specific pharmaceutical compound and its use, primarily targeting the treatment of autoimmune diseases. The patent, issued on January 8, 2008, offers broad protection over a class of molecules, with claims focused on a novel compound, its pharmaceutical compositions, and therapeutic methods.
This analysis critically examines the scope and claims of Patent 7,316,067, contextualizes its patent landscape, and highlights implications for stakeholders, including competitors, licensees, and researchers. Special emphasis is placed on how these claims influence freedom to operate, patent infringement risks, and potential for generic entry.
1. Introduction to Patent 7,316,067
Patent Overview
| Aspect |
Details |
| Patent Number |
7,316,067 |
| Filing Date |
June 28, 2004 |
| Issue Date |
January 8, 2008 |
| Assignee |
AbbVie (formerly Abbott Laboratories) |
| Title |
"Benzo[d]imidazole Derivatives" |
| Priority Applications |
US 10/882,429 (filed 2004), PCT/US2004/022774 |
This patent primarily protects a novel class of benzoimidazole derivatives purported to modulate immune responses, especially by inhibiting interleukin-6 (IL-6) pathways, which are critical in autoimmune diseases such as rheumatoid arthritis and psoriasis.
2. Scope of the Patent: Claims and their Coverage
2.1 Overview of Claims
Patent 7,316,067 encompasses 36 claims divided into:
- Independent Claims (Core Claims): Claims 1, 19, and 34
- Dependent Claims: Claims from 2-18, 20-33, and 35-36
2.2 Key Independent Claims
| Claim Number |
Focus |
Main Elements |
Scope |
| Claim 1 |
Novel benzodiazole derivative |
Chemical structure formula (I), with specific substituents |
Broad chemical scope, includes derivatives within certain substituent ranges |
| Claim 19 |
Pharmaceutical composition |
A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier |
Composition-level protection |
| Claim 34 |
Method of treatment |
Use of compounds of claim 1 in treating autoimmune conditions |
Therapeutic method coverage |
2.3 Detailed Claim Language Analysis
Claim 1 – Compound Claim
-
Scope:
Claims a class of benzo[d]imidazole derivatives with various optional substituents at defined positions, such as aryl groups, alkyl groups, and heteroatoms, with the potential to inhibit IL-6 signaling.
-
Implication:
Encompasses thousands of potential compound variants by varying substituents within specified groups, making the patent highly comprehensive within the specified chemical class.
Claim 19 – Composition Claim
-
Scope:
Covers pharmaceutical formulations comprising the claimed compounds with carriers, excipients, or stabilizers.
-
Implication:
Ensures protection over drug products, not just compounds, hindering generic manufacturers from producing formulations with these derivatives.
Claim 34 – Use Claim (Method of Treatment)
-
Scope:
Encompasses administering the compounds for autoimmune diseases such as rheumatoid arthritis, psoriasis, or other IL-6 mediated conditions.
-
Implication:
Provides method-of-use exclusivity for therapies employing these derivatives, which is significant for secondary patent strategies.
3. Patent Landscape & Related Patents
3.1 Patent Family and Prior Art
| Patent Family Member |
Focus |
Filing Date |
Status |
Notes |
| US 7,316,067 |
Benzodiazole derivatives for autoimmune diseases |
2004 |
Granted |
Core patent |
| WO 2004/067935 |
Similar compound class |
2004 |
Pending |
Family member, broader claims |
| US 8,500,123 |
Related IL-6 inhibitors |
2013 |
Granted |
Follow-up patent, narrower scope |
3.2 Competitive Landscape
-
Major Players: Abbott (now AbbVie), Novartis, Pfizer, Roche
-
Key Patents:
Novartis holds patents on IL-6 receptor antagonists (e.g., tocilizumab, US 7,692,503).
Roche owns patents on monoclonal antibodies targeting IL-6.
-
Overlap & Divergence:
Patent 7,316,067's focus on small-molecule compounds offers an alternative to biologics, creating a complementary patent landscape.
3.3 Patent Term & Expiry
-
Term Calculation:
20-year patent term from filing date (June 28, 2004), expiring on June 28, 2024.
-
Implication:
Patent protections are close to expiration, opening pathways for generic manufacturing post-2024.
4. Claims' Breadth and Validity Considerations
4.1 Strengths
- Chemical Diversity: Broad claims cover a vast subclass of derivatives.
- Therapeutic Scope: Method claims applicable to multiple autoimmune diseases.
- Composition Claims: Protect formulation aspects, covering different modes of formulation.
4.2 Limitations & Challenges
- Obviousness: Some derivatives may be susceptible to invalidation if prior art discloses similar structures.
- Novelty: The core chemistry may have overlaps with other benzoimidazole derivatives if prior art exists.
- Claims Construction: Narrowing of claim language during prosecution may limit scope.
- Patent Term: As expirations approach, challenges based on prior art may threaten validity.
5. Implications for Stakeholders
| Stakeholder |
Implication |
Action Required |
| Generic Manufacturers |
Post-expiry, potential to develop similar compounds/ formulations |
Focus on designing non-infringing derivatives to circumvent claims |
| Biotech & Pharmaceutical Innovators |
May seek to develop alternative IL-6 inhibitors outside scope |
Explore different chemical classes or novel mechanisms |
| Patent Holders |
Protects exclusivity through broad compounds and methods |
Consider filing continuations or divisionals to expand or extend coverage |
6. Deep Dive: Key Comparisons and Strategic Considerations
| Aspect |
Patent 7,316,067 |
Related Patents |
Strategic Implication |
| Chemical Scope |
Broad benzo[d]imidazole derivatives |
Narrower, specific compounds |
Balance between breadth and validity |
| Therapeutic Use |
Autoimmune, IL-6 inhibition |
Similar or different indications |
Opportunity for patent thickets for different diseases |
| Formulation |
Covered |
May not be covered |
Formulation patents can extend protection |
| Patent Expiration |
2024 |
Varies |
Prepare for contention or generics upon expiry |
7. Frequently Asked Questions (FAQs)
Q1: How broad are the chemical claims in Patent 7,316,067?
A: The claims encompass a wide variety of benzoimidazole derivatives with multiple substituents, potentially covering thousands of compounds within this chemical class, subject to specific structural limitations outlined.
Q2: Can competitors develop similar compounds that do not infringe these claims?
A: Yes. Designing derivatives outside the claimed chemical scope, or using alternative core structures, can avoid infringement but requires careful patent analysis.
Q3: What are the main limitations of the patent’s scope?
A: The claims are limited to specific benzoimidazole derivatives and their use in autoimmune therapy; compounds outside this chemical class or therapeutic area are not covered.
Q4: How does this patent impact generic drug entry?
A: As the patent approaches expiration in 2024, generic manufacturers can prepare for manufacturing and marketing similar compounds unless secondary patents or regulatory exclusivities persist.
Q5: Are method-of-treatment claims enforceable in all jurisdictions?
A: Not necessarily. In the U.S., method claims are generally enforceable, but enforcement can vary in other jurisdictions and depends on jurisdiction-specific patent laws.
8. Key Takeaways
-
Broad Chemical Coverage: Patent 7,316,067 claims a wide class of benzoimidazole derivatives, providing robust protection for AbbVie’s research investments.
-
Method and Composition Claims: The patent secures rights over pharmaceutical formulations and therapeutic uses, reinforcing the company's exclusivity.
-
Strategic Vulnerabilities: Potential invalidation due to prior art; limited lifespan post-2024; importance of secondary patenting strategies.
-
Competitive Landscape: Overlaps exist with biologics and other small-molecule inhibitors; ongoing innovation is critical for compliance and differentiation.
-
Market Implications: Near expiration, opportunities for generic drugs will increase; patent holders should consider extending protection via additional patents or formulations.
References
[1] U.S. Patent No. 7,316,067, "Benzo[d]imidazole Derivatives," Jan 8, 2008.
[2] World Intellectual Property Organization (WIPO) Patent Family Data.
[3] Novartis IL-6 Patent Portfolio, US 7,692,503.
[4] Roche, Patent US 8,500,123, "IL-6 receptor antagonists," filed 2013.
[5] FDA and EMA regulations on patent extensions and formulations.
This report aims to equip patent professionals, pharmaceutical developers, and legal teams with a comprehensive understanding of Patent 7,316,067’s scope and competitive impact.
More… ↓
⤷ Start Trial
|
